Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that it has entered into a Licence and Collaboration Agreement with LabCorp that will support the development of immuno-oncology products or services.

Marc Voigt, CEO of Immutep Said: “Over the years, Immutep has generated a significant amount of know-how in immuno-oncology, specifically in terms of LAG-3.”

Under the terms of the Agreement, Immutep is eligible to receive potential undisclosed milestone and service-related payments. The collaboration with LabCorp is unrelated to any of Immutep’s own in-house pharmaceutical development programs in cancer or autoimmune disease.

Related Posts

Subscribe Our Newsletter